vs

Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Kimco Realty (KIM). Click either name above to swap in a different company.

BIOMARIN PHARMACEUTICAL INC is the larger business by last-quarter revenue ($766.2M vs $542.5M, roughly 1.4× Kimco Realty). Kimco Realty runs the higher net margin — 27.9% vs 13.8%, a 14.0% gap on every dollar of revenue. On growth, Kimco Realty posted the faster year-over-year revenue change (3.2% vs 3.0%). Over the past eight quarters, Kimco Realty's revenue compounded faster (3.8% CAGR vs 3.7%).

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Kimco Realty Corporation, headquartered in Jericho, New York, is a real estate investment trust that invests in shopping centers.

BMRN vs KIM — Head-to-Head

Bigger by revenue
BMRN
BMRN
1.4× larger
BMRN
$766.2M
$542.5M
KIM
Growing faster (revenue YoY)
KIM
KIM
+0.2% gap
KIM
3.2%
3.0%
BMRN
Higher net margin
KIM
KIM
14.0% more per $
KIM
27.9%
13.8%
BMRN
Faster 2-yr revenue CAGR
KIM
KIM
Annualised
KIM
3.8%
3.7%
BMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BMRN
BMRN
KIM
KIM
Revenue
$766.2M
$542.5M
Net Profit
$106.0M
$151.2M
Gross Margin
74.6%
Operating Margin
16.9%
36.4%
Net Margin
13.8%
27.9%
Revenue YoY
3.0%
3.2%
Net Profit YoY
-9.0%
EPS (diluted)
$0.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMRN
BMRN
KIM
KIM
Q1 26
$766.2M
Q4 25
$874.6M
$542.5M
Q3 25
$776.1M
$535.9M
Q2 25
$825.4M
$525.2M
Q1 25
$745.1M
$536.6M
Q4 24
$747.3M
$525.4M
Q3 24
$745.7M
$507.6M
Q2 24
$712.0M
$500.2M
Net Profit
BMRN
BMRN
KIM
KIM
Q1 26
$106.0M
Q4 25
$-46.6M
$151.2M
Q3 25
$-30.7M
$137.8M
Q2 25
$240.5M
$163.0M
Q1 25
$185.7M
$132.8M
Q4 24
$124.9M
$166.0M
Q3 24
$106.1M
$136.0M
Q2 24
$107.2M
$119.7M
Gross Margin
BMRN
BMRN
KIM
KIM
Q1 26
74.6%
Q4 25
68.5%
Q3 25
82.0%
Q2 25
81.8%
Q1 25
79.7%
Q4 24
81.8%
Q3 24
74.7%
Q2 24
81.7%
Operating Margin
BMRN
BMRN
KIM
KIM
Q1 26
16.9%
Q4 25
-5.1%
36.4%
Q3 25
-6.0%
34.9%
Q2 25
33.5%
39.2%
Q1 25
30.0%
33.6%
Q4 24
21.6%
31.7%
Q3 24
15.3%
33.7%
Q2 24
16.9%
32.1%
Net Margin
BMRN
BMRN
KIM
KIM
Q1 26
13.8%
Q4 25
-5.3%
27.9%
Q3 25
-4.0%
25.7%
Q2 25
29.1%
31.0%
Q1 25
24.9%
24.8%
Q4 24
16.7%
31.6%
Q3 24
14.2%
26.8%
Q2 24
15.1%
23.9%
EPS (diluted)
BMRN
BMRN
KIM
KIM
Q1 26
$0.54
Q4 25
$-0.22
Q3 25
$-0.16
Q2 25
$1.23
Q1 25
$0.95
Q4 24
$0.65
Q3 24
$0.55
Q2 24
$0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMRN
BMRN
KIM
KIM
Cash + ST InvestmentsLiquidity on hand
$2.2B
$211.6M
Total DebtLower is stronger
$7.7B
Stockholders' EquityBook value
$6.2B
$10.4B
Total Assets
$8.6B
$19.7B
Debt / EquityLower = less leverage
0.74×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMRN
BMRN
KIM
KIM
Q1 26
$2.2B
Q4 25
$1.3B
$211.6M
Q3 25
$1.3B
$159.3M
Q2 25
$1.2B
$226.6M
Q1 25
$1.0B
$131.3M
Q4 24
$942.8M
$688.6M
Q3 24
$675.4M
$789.0M
Q2 24
$972.1M
$126.4M
Total Debt
BMRN
BMRN
KIM
KIM
Q1 26
Q4 25
$7.7B
Q3 25
Q2 25
Q1 25
Q4 24
$8.0B
Q3 24
Q2 24
Stockholders' Equity
BMRN
BMRN
KIM
KIM
Q1 26
$6.2B
Q4 25
$6.1B
$10.4B
Q3 25
$6.1B
$10.5B
Q2 25
$6.0B
$10.5B
Q1 25
$5.8B
$10.6B
Q4 24
$5.7B
$10.7B
Q3 24
$5.4B
$10.5B
Q2 24
$5.3B
$10.6B
Total Assets
BMRN
BMRN
KIM
KIM
Q1 26
$8.6B
Q4 25
$7.6B
$19.7B
Q3 25
$7.6B
$19.9B
Q2 25
$7.5B
$19.8B
Q1 25
$7.1B
$19.7B
Q4 24
$7.0B
$20.3B
Q3 24
$6.9B
$20.1B
Q2 24
$7.1B
$19.5B
Debt / Equity
BMRN
BMRN
KIM
KIM
Q1 26
Q4 25
0.74×
Q3 25
Q2 25
Q1 25
Q4 24
0.75×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMRN
BMRN
KIM
KIM
Operating Cash FlowLast quarter
$220.7M
$258.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
2.08×
1.71×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMRN
BMRN
KIM
KIM
Q1 26
$220.7M
Q4 25
$99.6M
$258.4M
Q3 25
$368.7M
$332.4M
Q2 25
$185.3M
$305.4M
Q1 25
$174.4M
$223.8M
Q4 24
$185.6M
$239.5M
Q3 24
$221.5M
$295.9M
Q2 24
$118.8M
$294.1M
Free Cash Flow
BMRN
BMRN
KIM
KIM
Q1 26
Q4 25
$58.9M
Q3 25
$340.2M
Q2 25
$168.2M
Q1 25
$157.6M
$205.4M
Q4 24
$166.1M
Q3 24
$203.0M
Q2 24
$97.4M
FCF Margin
BMRN
BMRN
KIM
KIM
Q1 26
Q4 25
6.7%
Q3 25
43.8%
Q2 25
20.4%
Q1 25
21.2%
38.3%
Q4 24
22.2%
Q3 24
27.2%
Q2 24
13.7%
Capex Intensity
BMRN
BMRN
KIM
KIM
Q1 26
Q4 25
4.7%
0.0%
Q3 25
3.7%
0.0%
Q2 25
2.1%
0.0%
Q1 25
2.3%
3.4%
Q4 24
2.6%
Q3 24
2.5%
Q2 24
3.0%
Cash Conversion
BMRN
BMRN
KIM
KIM
Q1 26
2.08×
Q4 25
1.71×
Q3 25
2.41×
Q2 25
0.77×
1.87×
Q1 25
0.94×
1.69×
Q4 24
1.49×
1.44×
Q3 24
2.09×
2.18×
Q2 24
1.11×
2.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons